An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
This study is designed to treat multiple solid tumor cancers. This type of study is done because of how the drug is expected to work against cancer. This study will enroll patients who have been previously treated for locally advanced or metastatic malignant solid tumors, including:
- Hormone receptor positive/ human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer
- Triple negative breast cancer (TNBC)
- Squamous non-small cell lung cancer (Squamous NSCLC)
- Non-squamous non-small cell lung cancer (Non-squamous NSCLC)
- Head and neck cancer
- Gastric or gastroesophageal junction (GEJ) or esophageal cancer
Enfortumab vedotin (PADCEV) has been approved by the FDA for the treatment of bladder cancer and cancers of the urinary tract. Enfortumab vedotin is expected to work by attacking cells that have a protein called Nectin-4. This protein is commonly found in cancer cells, specifically in those listed above.
If you are interested in more information on this study, please contact us. Refer to the Astellas study. You can also find information on this study by going to clinicaltrials.gov website and searching for NCT04225117.